ArticleCureus2026
Effect of Preoperative Superselective Embolization in the Resection of Hypervascular Tumors of the Central Nervous System, Neck, and Nasal Cavity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hypervascular head and neck tumors, such as paragangliomas, esthesioneuroblastomas, and juvenile nasopharyngeal angiofibromas (JNA), are surgically challenging due to their rich vascular supply and proximity to critical structures. Preoperative superselective embolization may optimize surgical outcomes by reducing intraoperative bleeding and facilitating safe resections. Methods We conducted a retrospective case-control study of patients with hypervascular tumors of the central nervous system, neck, and nasal cavity treated between 2019 and 2024 at a single tertiary neurosurgical center. Patients were divided into embolization and non-embolization groups. Outcomes included the extent of resection, intraoperative blood loss, transfusion requirements, operative time, hospital stay, and complications. Results Fifty patients were analyzed (mean age 42.9 years; 58% female). Half underwent preoperative embolization, more frequently in nasal tumors (64%). Diagnoses included paraganglioma (46%), JNA (28%), and esthesioneuroblastoma (26%). Ethylene-vinyl alcohol copolymer was used in 96% of embolizations. Embolized patients had higher complete resection rates (100% vs. 84.6%; p<0.001), less blood loss (263.7 vs. 978.0 mL; p<0.001), fewer transfusions (16% vs. 84%; OR: 27.56), and shorter hospital stays (1.84 vs. 6.00 days; p<0.001). Complications were uncommon (8%) and transient. Conclusion Preoperative superselective embolization, particularly with ethylene-vinyl alcohol copolymer, is a safe and effective adjunct that improves resection rates, reduces perioperative morbidity, and optimizes surgical outcomes in hypervascular head and neck tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.